- Tetra, Targeted Pharmaceutical and the George Mason University National Center for Biodefense and Infectious Diseases (NCBID) sign a research collaboration
- ARDS-003 to be evaluated in Sars-CoV-2 infected animals at the Biocontainment Laboratory-George Mason University NCBID
OTTAWA, ON / ACCESSWIRE / October 22, 2020 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) ( TSX:TBP )( OTCQB:TBPMF ), a leader in cannabinoid-derived drug discovery and development, is excited to announce that it has signed a research collaboration agreement with Targeted Pharmaceutical and the George Mason University NCBID. As previously disclosed last quarter, Tetra officially acquired a 20% minority stake in Targeted Pharmaceutical. As per the Officer Certificate provided to the TSX, Targeted is in compliance with all applicable laws in the jurisdictions in which they operate.
The NCBID is a leading institute conducting pioneering research on infectious diseases including diagnostic, therapeutics, and vaccine development. The research collaboration will allow the evaluation of ARDS-003, with and without antiviral drugs, to prevent and treat SARS-CoV-2 infection in animals.
Under the leadership of Dr. Lance Liotta, Chief Medical Officer at Targeted Therapeutics, and Professor at the George Mason University, ARDS-003 will be studied in SARS-CoV-2 infected animals to further understand its potential as a preventive and therapeutic medicine. This research will be performed by Dr. Liotta’s team at the Biocontainment Laboratory-George Mason University NCBID. Dr. Liotta has served as Co-Director and Co-Founder of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at the George Mason University. Prior to this appointment, Dr. Liotta served as Chief of the Laboratory of Pathology, NCI, Deputy Director of NIH, Co-Director of the NCI/FDA Clinical Proteomics Program, and Director of the Anatomic Pathology Residency Program.
Dr. Guy Chamberland, CEO and CRO commented, “We have initiated this research agreement to generate new intellectual property and work closer with key researchers in the USA who are investigating therapeutic agents for treatment of patients who are severely ill from COVID-19. Teaming up with Targeted Pharmaceutical opened the door to a collaboration with a prestigious USA research laboratory at the George Mason University. Having the ability to study investigational new drugs in animals who are infected with the COVID-19 virus is a major opportunity for us. The research team will gain tremendous knowledge on the role a cytokine release modulating drug plays in COVID-19 infections. This type of animal research was used to study potential drug candidates for Middle East Respiratory Syndrome (MERS-CoV) and most recently the REGN-COV2 antibody in SARS-CoV-2 infected animals. The Company is not making any expressed or implied claims that its product has the ability to eliminate, cure and/or contain the COVID-19 or the SARS-COV-2 virus at this time. ”
About George Mason University
George Mason University is Virginia’s largest public research university. Located near Washington, D.C., Mason enrolls more than 37,000 students from 130 countries and all 50 states. The National Center for Biodefense and Infectious Diseases (NCBID) at Mason focuses on host-pathogen interactions using proteomics and nanotechnology as they are applied to diagnostic, therapeutic, and vaccine development.